HERCEPTIN®
(Trastuzumab)
Documentation
Patented
Approved 1998
FDA Letter
FDA Label
Full Sequence
Brief Summary
Function Type: Antagonist
Target: CD340(HER2)
Indication Category: Cancer
Patented
Approved 1998
FDA Letter
FDA Label
Full Sequence
Function Type: Antagonist
Target: CD340(HER2)
Indication Category: Cancer